A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer

Trial Profile

A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Sep 2012 Planned number of patients changed from 42 to 43 as reported by ClinicalTrials.gov.
    • 14 Sep 2012 Planned number of patients changed from 42 to 43 as reported by ClinicalTrials.gov.
    • 14 Sep 2012 Planned end date 1 Nov 2017 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top